Berrocal, AArance, ACastellon, V Ede la Cruz, LEspinosa, ECao, M GLarriba, J L GMárquez-Rodas, ISoria, AAlgarra, S M2023-01-252023-01-252017-11-07http://hdl.handle.net/10668/11780All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AdjuvantB-RAFImmunotherapyMelanomaMetastaticCombined Modality TherapyHumansMelanomaresearch article29116432open access10.1007/s12094-017-1768-11699-3055PMC5785602https://link.springer.com/content/pdf/10.1007/s12094-017-1768-1.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785602/pdf